Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07240987
PHASE1/PHASE2

Mesenchymal Stem Cells for Chronic Kidney Diseases

Sponsor: The First Affiliated Hospital of Air Force Medicial University

View on ClinicalTrials.gov

Summary

This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.

Official title: A Randomized Controlled Study of Mesenchymal Stem Cells in the Treatment of Chronic Kidney Diseases

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-01-01

Completion Date

2027-08-31

Last Updated

2025-12-24

Healthy Volunteers

No

Interventions

DRUG

0.9% sodium chloride

The control group will receive a placebo, which is an intravenous infusion of 250 mL of 0.9% sodium chloride injection.

DRUG

MSCs

The experimental group will receive an intravenous injection of allogeneic MSCs at a dose of 1.0×10⁶ cells per kilogram, reconstituted with 250 mL of sodium chloride injection.